Medical Cannabis for Children: Limited Evidence Supports Only Specific Cases Under Close Supervision
A clinical review found insufficient evidence for medical cannabis efficacy or safety in children for any condition, with growing data suggesting possible harm, though specific cases like refractory epilepsy may warrant carefully monitored use.
Quick Facts
What This Study Found
This clinical review examined the evidence for medical cannabis use in children, prompted by case reports of children with refractory epilepsy responding to cannabis-based treatments. The author concluded that overall evidence is insufficient to support either the efficacy or safety of cannabis use for any indication in children.
The review emphasized several concerns: an increasing body of data suggests possible harm, particularly in conditions where the developing brain may be vulnerable. Smoking is explicitly rejected as an acceptable delivery method for children. The review also cautioned that therapeutic use in specific medical cases should not be used to justify recreational cannabis use by adolescents.
Despite these concerns, the author acknowledged that exceptional cases exist where standard treatments have failed, and offered recommendations for therapeutic use in these circumstances: always under careful individual evaluation, within well-designed research studies, and with ongoing monitoring for both safety and efficacy.
Key Numbers
No specific numerical data were presented; the review synthesized existing evidence and provided clinical recommendations.
How They Did This
This was a narrative clinical review published in Paediatrics & Child Health (a journal of the Canadian Paediatric Society), summarizing available evidence on cannabis use in pediatric populations and providing clinical recommendations.
Why This Research Matters
Medical cannabis for children is among the most contentious topics in pediatric medicine. This review from a mainstream pediatric journal represents the medical establishment's cautious position: acknowledge that some children may benefit, particularly those with refractory epilepsy, but insist on rigorous evaluation and monitoring rather than broad access.
The Bigger Picture
The tension between anecdotal reports of children with severe epilepsy responding dramatically to cannabis-based treatments and the lack of rigorous safety and efficacy data exemplifies the broader challenge of cannabis medicine. The stakes are especially high in children because of the developing brain's sensitivity to cannabinoids.
What This Study Doesn't Tell Us
This is a narrative review reflecting one author's interpretation of available evidence, published before many subsequent clinical trials of pharmaceutical-grade CBD products in pediatric epilepsy. The review predates the FDA approval of Epidiolex (cannabidiol) for pediatric seizure disorders.
Questions This Raises
- ?Have subsequent clinical trials of pharmaceutical CBD products changed the risk-benefit calculus for children with epilepsy?
- ?Should cannabis-based treatments for children be limited to pharmaceutical-grade products with standardized dosing?
- ?How do we balance parental autonomy with medical caution when standard treatments fail?
Trust & Context
- Key Stat:
- Insufficient data to support cannabis efficacy or safety for any pediatric indication as of 2016.
- Evidence Grade:
- Moderate evidence from a narrative clinical review in a reputable pediatric journal, synthesizing available data and providing consensus-oriented recommendations.
- Study Age:
- Published in 2016, before the FDA approved Epidiolex (CBD) for pediatric epilepsy in 2018. The evidence landscape for pediatric cannabis use has changed significantly.
- Original Title:
- Is the medical use of cannabis a therapeutic option for children?
- Published In:
- Paediatrics & child health, 21(1), 31-4 (2016)
- Authors:
- Rieder, Michael J
- Database ID:
- RTHC-01250
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medical cannabis safe for children?
As of this 2016 review, there was insufficient evidence to establish safety for any pediatric use. The review noted growing data suggesting possible harm to the developing brain. Since then, pharmaceutical CBD (Epidiolex) has been approved for specific seizure disorders with established dosing and monitoring protocols.
Can cannabis treat childhood epilepsy?
Case reports existed at the time of this review showing benefit for refractory epilepsy. The author recommended use only in exceptional cases with careful monitoring. Since 2018, pharmaceutical CBD has received FDA approval for specific pediatric seizure disorders based on clinical trial evidence.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01250APA
Rieder, Michael J. (2016). Is the medical use of cannabis a therapeutic option for children?. Paediatrics & child health, 21(1), 31-4.
MLA
Rieder, Michael J. "Is the medical use of cannabis a therapeutic option for children?." Paediatrics & child health, 2016.
RethinkTHC
RethinkTHC Research Database. "Is the medical use of cannabis a therapeutic option for chil..." RTHC-01250. Retrieved from https://rethinkthc.com/research/rieder-2016-is-the-medical-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.